MonoSol Rx Appoints Dr. Mary Ellen Norvitch Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance

Industry Veteran to Support Rapidly Advancing Pipeline

Warren, NJ (June 17, 2010) – MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the appointment of Mary Ellen Norvitch, Ph.D. to the newly created position of Vice President, Regulatory Affairs/Clinical Affairs/Quality Assurance.  Effective immediately, Dr. Norvitch will report to A. Mark Schobel, President and Chief Executive Officer.

Mr. Schobel said, “We are pleased to welcome Mary Ellen to MonoSol Rx as we prepare for the FDA approvals of our first two prescription film products and aggressively continue to develop our PharmFilm-based pipeline candidates. Her leadership will be of great value as we expand our regulatory, clinical and quality assurance functions to support our upcoming marketing applications and product approval processes.  As we continue both self-funded and partnered initiatives in targeted therapeutic areas and patient populations, Mary Ellen will make a significant contribution in guiding our regulatory affairs and clinical efforts.”

Prior to joining MonoSol Rx, Dr. Norvitch held numerous executive level positions in major pharmaceutical and specialty pharmaceutical organizations.  Most recently, she built the U.S. regulatory function for ProStrakan, Inc., a specialty pharmaceutical company. As Vice President, US Regulatory Affairs, Dr. Norvitch led her team through the successful U.S. new drug application (NDA) review and Food and Drug Administration (FDA) approval of  SANCUSO® Transdermal System.

Prior to ProStrakan, Dr. Norvitch held positions of increasing responsibility and complexity within Bristol Myers Squibb, Schering Plough, Watson Pharmaceuticals, Pfizer, Inc and Barrier Therapeutics. She started her industry career with American Cyanamid in the Clinical Research - Oncology field, serving as clinical team leader for a Phase I program.

Dr. Norvitch earned her B.S. in Chemistry and a PhD. in Pathobiology from the University of Minnesota.  She completed postdoctoral training at the Mayo Clinic in Molecular Biology.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver unique proprietary pharmaceutical drug films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company’s leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm® technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company’s commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
  • This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Please complete our short form to speak with a business development specialist.